Upregulation of the HGF/c-MET axis has determined acquired resistance to lenvatinib in a preclinical model of HCC [52], suggesting its potential role as a therapeutic target to overcome lenvatinib resistance, particularly in light of the high percentage of HCC patients overexpressing these two molecules [53]. The gene discussed is HGF; the disease is hepatocellular carcinoma.